Eli Lilly (NYSE: LLY) has announced results from a Phase III study of lebrikizumab, an investigational therapy designed to treat atopic dermatitis in people wit 11 March 2024
Research undertaken by Californian antiviral specialist Gilead Sciences and fellow American company Merck & Co is moving in the right direction, new data show. 8 March 2024
Another encouraging result in the growth area of antibody-drug conjugates (ADC) reveals a significant survival benefit for people with multiple myeloma. 6 February 2024
Blueprint Medicines Corporation has outlined its 2024 corporate strategy, promising accelerated revenue growth, sustainable research and development, and a clea 9 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.